Allison Transmission Is Too Cheap To Drive Past

Allison Transmission's Q2 revenue nearly doubled to $1.57B, driven by its $2.7B Dana Off-Highway acquisition, while adjusted net income and EBITDA also improved materially. Management expects 2026 revenue of $5.8–$6B, net profit of $600–$700M—including $140M in deal expenses—and EBITDA of $1.465–$1.575B. The article maintains a Buy view, arguing the market undervalues the acquisition and expected synergies.

Analysis

Acquisition-adjusted growth is not yet proof of a higher-quality earnings base: the key valuation question is whether the acquired business adds durable, cash-generative earnings after deal costs and integration—not whether consolidated revenue has stepped up. The 2026 outlook gives investors a near-term test, but the stated $140M of deal expenses makes reported and adjusted performance especially important to reconcile. Verify organic revenue, segment EBITDA, free-cash-flow conversion, leverage and realized synergies before underwriting the full “transformation” thesis.

ALSN’s upside is operating leverage and a broader off-highway footprint if integration succeeds. The counterweight is greater exposure to cyclical end markets and execution risk; weaker construction, mining or agricultural demand could obscure synergies and pressure utilization. Dana may benefit from the transaction proceeds and a narrower business, so a simple long-ALSN/short-DAN pair is not compelling without evidence on Dana’s post-sale balance sheet and retained-business outlook.

Near term, the market may reward guidance delivery; over 1–3 months, segment disclosure and cash conversion should determine whether the acquisition premium holds. Over 6–18 months, cycle conditions and synergy realization matter more than headline growth. Contrarian view: the positive narrative may be over-crediting acquired revenue while underweighting integration costs and cyclicality. This is a conditional, moderately positive setup—not an unconditional Buy.

Key Decisions for Investors

• Consider a staged long in ALSN only after reviewing the next results for organic growth, segment EBITDA, free-cash-flow conversion and progress against synergy targets; do not treat acquired revenue as synergy evidence.
• Reassess or reduce exposure if management lowers the 2026 outlook, acquired-business profitability disappoints, deal costs persist beyond expectations, or cash conversion weakens despite reported EBITDA growth.
• Keep DAN off the short leg for now. Revisit only after checking transaction-proceeds use, leverage and outlook for its retained operations; these factors could make the divestiture beneficial to Dana shareholders.
• Monitor end-market demand and integration updates over the next 1–3 quarters. Strong synergy realization with stable cash generation supports the thesis; deteriorating demand or repeated guidance caveats would falsify it.